{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:05:02Z","timestamp":1789344302811,"version":"build-2803163510"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>Vaccination is proven to significantly reduce the risk of human papillomavirus (HPV)\u2013related complications, especially cervical cancer. This study aimed to assess the immunogenicity and safety of the investigational bivalent HPV vaccine (16\/18), named Papilloguard (Noyan Pajouhan Biopharma, Tehran, Iran), in comparison with the reference product (Cervarix, bivalent HPV vaccine (16\/18) manufactured by GlaxoSmithKline, Rixensart, Belgium) in a three-dose regimen.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This trial was a randomized, controlled, double-blind, phase III study of two HPV vaccines in healthy female volunteers aged 15\u201325. The primary endpoint was to test the noninferiority of Papilloguard (Noyan Pajouhan Biopharma) to Cervarix (GlaxoSmithKline) as measured by the geometric mean titer (GMT) ratios of HPV-16 and HPV-18 7 months after the first vaccination. Secondary endpoints were the proportion of local and systemic solicited and unsolicited events, and the number of females with seroconversion against HPV-16 and HPV-18 7 months after the first vaccination.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Out of 504 screened women, 218 were enrolled. Seven months after the first vaccination, GMT ratios of HPV-16 and HPV-18 were 0.59 and 0.93, respectively. The seroconversion rates of both Papilloguard (Noyan Pajouhan Biopharma) and Cervarix (GlaxoSmithKline) were more than 96%. Both vaccinated groups had a generally good profile of solicited and unsolicited adverse events (AEs). The most common AE was discomfort at the injection site, which was well tolerated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The result analysis of this study supports the noninferiority of Papilloguard (Noyan Pajouhan Biopharma) to Cervarix (GlaxoSmithKline) in terms of safety and immunogenicity based on the GMT ratio. However, long-term comparative studies to evaluate the sustainability of GMT response and risk of cervical intraepithelial neoplasia grades 2\u20133 are needed.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cej.0000000000000753","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T11:01:00Z","timestamp":1648638060000},"page":"558-567","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Immunogenicity and safety of a bivalent, adjuvant system 04\u2013adjuvanted human papillomavirus vaccine in healthy female volunteers aged 15\u201325: a randomized, double-blind, phase III, noninferiority clinical trial"],"prefix":"10.1097","volume":"31","author":[{"given":"Seyyedeh Maryam","family":"Afshani","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, Tehran University of Medical Sciences"},{"name":"Medical Department, Arta Pharmed Company"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reihaneh","family":"Mirhassani","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, College of Science, University of Tehran"},{"name":"Noyan Pajouhan Biopharma, Biotechnology Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Hosseini","sequence":"additional","affiliation":[{"name":"Clinical Trial Center, Tehran University of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reihaneh","family":"Hosseini","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Arash Women\u2019s Hospital, Tehran University of Medical Science"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsaneh","family":"Tehranian","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Arash Women\u2019s Hospital, Tehran University of Medical Science"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Malekzadeh","sequence":"additional","affiliation":[{"name":"Liver and Pancreatobiliary Diseases Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afshin","family":"Ostovar","sequence":"additional","affiliation":[{"name":"Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Hossein","family":"Abdolghaffari","sequence":"additional","affiliation":[{"name":"Noyan Pajouhan Biopharma, Biotechnology Research Center"},{"name":"Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University"},{"name":"Gastrointestinal Pharmacology Interest Group (GPIG), Universal Scientific Education and Research Network (USERN), Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Amin","family":"Ghobadi","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Tehran University of Medical Sciences"},{"name":"Medical Department, Arta Pharmed Company"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnaz","family":"Hedayatjoo","sequence":"additional","affiliation":[{"name":"Medical Department, Arta Pharmed Company"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delara","family":"Hazegh Fetratjoo","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Tehran University of Medical Sciences"},{"name":"Medical Department, Arta Pharmed Company"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Rezagholi","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Tehran University of Medical Sciences"},{"name":"Medical Department, Arta Pharmed Company"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AmirHossein","family":"Anari","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Tehran University of Medical Sciences"},{"name":"Medical Department, Arta Pharmed Company"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Moini","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Arash Women\u2019s Hospital, Tehran University of Medical Science"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,3,29]]},"reference":[{"key":"R1-20250527","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/S2214-109X(19)30482-6","article-title":"Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis.","volume":"8","author":"Arbyn","year":"2020","journal-title":"Lancet Glob Health"},{"key":"R2-20250527","first-page":"CD009069","article-title":"Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.","volume":"5","author":"Arbyn","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"R3-20250527","first-page":"14","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"81","year":"2014","journal-title":"J Am Coll Dent"},{"key":"R4-20250527","first-page":"CD013479","article-title":"Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.","volume":"2019","author":"Bergman","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"R5-20250527","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ygyno.2006.07.019","article-title":"Prevention strategies of cervical cancer in the HPV vaccine era.","volume":"103","author":"Bosch","year":"2006","journal-title":"Gynecol Oncol"},{"key":"R6-20250527","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.","volume":"199","author":"Brown","year":"2009","journal-title":"J Infect Dis"},{"key":"R7-20250527","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1086\/657321","article-title":"Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings.","volume":"202","author":"Bruni","year":"2010","journal-title":"J Infect Dis"},{"key":"R8a-20250527","first-page":"626","article-title":"FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP).","volume":"59","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R8-20250527","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.30716","article-title":"Worldwide burden of cancer attributable to HPV by site, country and HPV type.","volume":"141","author":"de Martel","year":"2017","journal-title":"Int J Cancer"},{"key":"R9-20250527","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"key":"R10-20250527","doi-asserted-by":"crossref","first-page":"332","DOI":"10.4161\/hv.5.5.7211","article-title":"Safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials.","volume":"5","author":"Descamps","year":"2009","journal-title":"Hum Vaccin"},{"key":"R11-20250527","doi-asserted-by":"crossref","first-page":"6186","DOI":"10.4049\/jimmunol.0901474","article-title":"AS04, an aluminum salt-and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity.","volume":"183","author":"Didierlaurent","year":"2009","journal-title":"J Immunol"},{"key":"R12-20250527","doi-asserted-by":"crossref","first-page":"705","DOI":"10.4161\/hv.5.10.9518","article-title":"Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.","volume":"5","author":"Einstein","year":"2009","journal-title":"Hum Vaccin"},{"key":"R13-20250527","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2174\/157339410791202574","article-title":"Innate immunity and vaccine adjuvants: from concepts to the development of a unique adjuvant system AS04 used for the formulation of a human papillomavirus (HPV) vaccine.","volume":"6","author":"Garcon","year":"2010","journal-title":"Curr Cancer Ther Rev"},{"issue":"Suppl","key":"R14-20250527","doi-asserted-by":"crossref","first-page":"136","DOI":"10.4161\/hv.7.0.14576","article-title":"Safety and tolerability of bivalent HPV vaccine: an Italian post-licensure study.","volume":"7","author":"Gasparini","year":"2011","journal-title":"Hum Vaccin"},{"key":"R15-20250527","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.bej.2018.12.011","article-title":"Comprehensive study on wave bioreactor system to scale up the cultivation of and recombinant protein expression in baculovirus-infected insect cells.","volume":"143","author":"Ghasemi","year":"2019","journal-title":"Biochem Eng J"},{"key":"R16-20250527","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1016\/j.vaccine.2006.06.005","article-title":"Enhanced humoral and memory B cellular immunity using HPV16\/18 L1 VLP vaccine formulated with the MPL\/aluminium salt combination (AS04) compared to aluminium salt only.","volume":"24","author":"Giannini","year":"2006","journal-title":"Vaccine"},{"key":"R17-20250527","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"key":"R18-20250527","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/infdis\/jiaa617","article-title":"Sustained cross-reactive antibody responses after human Papillomavirus vaccinations: up to 12 years follow-up in the Finnish Maternity Cohort.","volume":"223","author":"Kann","year":"2021","journal-title":"J Infect Dis"},{"key":"R19-20250527","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3802\/jgo.2011.22.2.67","article-title":"Human papillomavirus 16\/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in 15-25 years old healthy Korean women.","volume":"22","author":"Kim","year":"2011","journal-title":"J Gynecol Oncol"},{"key":"R20-20250527","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/IGC.0b013e3181a23c0e","article-title":"Immunogenicity, reactogenicity, and safety of human papillomavirus 16\/18 AS04-adjuvanted vaccine in Japanese women: interim analysis of a phase II, double-blind, randomized controlled trial at month 7.","volume":"19","author":"Konno","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"R21-20250527","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40264-013-0039-5","article-title":"Safety of human papillomavirus vaccines: a review.","volume":"36","author":"Macartney","year":"2013","journal-title":"Drug Saf"},{"key":"R22-20250527","doi-asserted-by":"crossref","first-page":"S367","DOI":"10.1093\/infdis\/jiaa621","article-title":"Human Papillomavirus vaccines.","volume":"224","author":"Markowitz","year":"2021","journal-title":"J Infect Dis"},{"key":"R23-20250527","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.4161\/hv.29532","article-title":"Sustained efficacy, immunogenicity, and safety of the HPV-16\/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination.","volume":"10","author":"Naud","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"R24-20250527","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1001\/jama.2011.407","article-title":"Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial.","volume":"305","author":"Neuzil","year":"2011","journal-title":"JAMA"},{"key":"R25-20250527","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"key":"R26-20250527","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.4161\/hv.28022","article-title":"Immune response to the HPV-16\/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study.","volume":"10","author":"Romanowski","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"R27-20250527","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.4161\/hv.7.12.18322","article-title":"Immunogenicity and safety of the HPV-16\/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule: results from a randomized study.","volume":"7","author":"Romanowski","year":"2011","journal-title":"Hum Vaccin"},{"key":"R28-20250527","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s12325-009-0079-5","article-title":"Clinical update of the AS04-adjuvanted human papillomavirus-16\/18 cervical cancer vaccine, Cervarix \u00ae.","volume":"26","author":"Schwarz","year":"2009","journal-title":"Adv Ther"},{"key":"R30-20250527","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s11606-010-1513-8","article-title":"Understanding equivalence and noninferiority testing.","volume":"26","author":"Walker","year":"2011","journal-title":"J Gen Intern Med"},{"key":"R32-20250527","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1016\/j.vaccine.2015.06.052","article-title":"Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: a randomized controlled phase 2 clinical trial.","volume":"33","author":"Wu","year":"2015","journal-title":"Vaccine"}],"container-title":["European Journal of Cancer Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CEJ.0000000000000753","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T16:05:02Z","timestamp":1748361902000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CEJ.0000000000000753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,29]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/cej.0000000000000753","relation":{},"ISSN":["0959-8278"],"issn-type":[{"value":"0959-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,29]]}}}